LAWRENCE, Kan., Sept. 22, 2021 /PRNewswire/ — Endpoints News this morning unveiled the 2021 Endpoints 11 — the most promising biotech startup companies of the year. “This year more than ever before, we see biotechs raising unprecedented amounts of money to pursue dramatic new gains in therapeutics,” says John Carroll, the founding editor of Endpoints. “But money isn’t enough. The Endpoints 11 is a list of companies with a shot at doing something big — and they’re taking on some big risks in a swing for the fences.”
“Every year, Endpoints 11 represents the best of biotech — and the best of Endpoints News.”
The 2021 Endpoints 11 winners are:
- Affinia Therapeutics
- Amylyx Pharmaceuticals
- Calico
- Dewpoint Therapeutics
- Dyno Therapeutics
- eGenesis
- Eikon Therapeutics
- Prime Medicine
- Scorpion Therapeutics
- Senti Biosciences
- Tectonic Therapeutic
The 2021 Endpoints 11 is sponsored by Catalent. John Chiminski, Catalent’s chairman and CEO, will present the awards live alongside Endpoints’ John Carroll at a virtual event for subscribers at 3 pm ET on September 22.
Attendees will see exclusive footage of John Carroll talking biotech with the teams behind the Endpoints 11. The event will conclude with a fireside chat between Carroll and a group of VCs behind some of the hottest startups in the field: Jürgen Eckhardt (Leaps by Bayer), Helen Kim (Vida Ventures), and Jean-Francois Formela (Atlas Venture).
“Every year, Endpoints 11 represents the best of biotech — and the best of Endpoints News,” says Endpoints founding publisher Arsalan Arif. “We’re celebrating science and entrepreneurship and telling stories about creating the fastest companies in biopharma, from the ground up, with all the risks and potential rewards. It’s great fun. Thanks to our sponsors Catalent and Egnyte for making this event possible.”
There is no charge to attend Endpoints 11, and registration is open to all biopharma professionals at eleven21.endpts.com. The web feature with profiles on each company is available to Endpoints readers with a premium subscription at ENDPTS.COM.
Founded in 2016 by editor John Carroll and publisher Arsalan Arif, Endpoints is an independent news media company covering drug development with 125,000 daily email subscribers. Endpoints News is also available on the web at ENDPTS.COM.
There’s no cost for a Basic subscription, which provides readers access to daily news content and special features like the Endpoints 11. A paid Insider subscription grants access to the entire content library and provides an ad-free experience. And the unlimited-seat Enterprise program gives companies of all sizes access to Endpoints for one flat price. Endpoints News has transitioned its global events online and is committed to providing free access for attendees throughout 2021. On December 7, Endpoints News hosts Women in Biopharma: 20 of the top women leaders in biopharma R&D 2021.
